

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3433824

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	WING-SZE LO	12/21/2012
RECEIVING PARTY DATA		
Name:	PANGU BIOPHARMA LIMITED	
Street Address:	18/F, EDINBURGH TOWER, THE LANDMARK	
Internal Address:	15 QUEEN'S ROAD CENTRAL	
City:	HONG KONG	
State/Country:	CHINA	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	14620817
CORRESPONDENCE DATA		
Fax Number:	(202)842-7899	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	(202) 842-7800	
Email:	wthomas@cooley.com	
Correspondent Name:	WENDY THOMAS	
Address Line 1:	1299 PENNSYLVANIA, SUITE 700	
Address Line 2:	PATENT DEPARTMENT/ATTN: MARK ROGEL	
Address Line 4:	WASHINGTON, D.C. 20004	
ATTORNEY DOCKET NUMBER:	ATYR-02602US_PANGU	
NAME OF SUBMITTER:	MARK E. ROGEL	
SIGNATURE:	/Mark E. Rogel/	
DATE SIGNED:	07/10/2015	
Total Attachments: 4		
source=ATYR-02602US_PANGU_ASSIGN#page1.tif		
source=ATYR-02602US_PANGU_ASSIGN#page2.tif		
source=ATYR-02602US_PANGU_ASSIGN#page3.tif		
source=ATYR-02602US_PANGU_ASSIGN#page4.tif		

ASSIGNMENT

PATENT

Wing-Sze Lo, having a post office address of Room 815, Sui Ming House, Siu Sai Wan Estate, Chai Wan, Hong Kong, China, (referred to as "Assignor") has made invention(s) (the "Invention(s)") set forth in applications for patent of the United States, and which are:

Application No.	Title	International Filing Date
PCT/US2011/033988 13/643,735	INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF CYSTEINYL-TRNA SYNTHETASE	April 26, 2011
PCT/US2011/034203 13/643,738	INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ISOLEUCYL TRNA SYNTHETASES	April 27, 2011
PCT/US2011/034207 13/643,730	INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF THRBONYL-TRNA SYNTHETASES	April 27, 2011
PCT/US2011/034387 13/643,753	INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ALANYL-TRNA SYNTHETASES	April 28, 2011
PCT/US2011/034388 13/643,745	INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ASPARAGINYL TRNA SYNTHETASES	April 28, 2011
PCT/US2011/034626 13/695,229	INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF VALYL-TRNA SYNTHETASES	April 29, 2011
PCT/US2011/034838 13/696,042	INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED PROTEIN FRAGMENTS OF ARGINYL-TRNA SYNTHETASES	May 2, 2011
PCT/US2011/035056 13/696,044	INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF METHIONYL-TRNA SYNTHETASES	May 3, 2011
PCT/US2011/035053 13/696,046	INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF PHENYLALANYL-ALPHA-TRNA SYNTHETASES	May 3, 2011
PCT/US2011/034840 13/696,047	INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF SERYL-TRNA SYNTHETASES	May 2, 2011
PCT/US2011/035250 13/696,048	INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF GLUTAMYL-PROLYL-TRNA SYNTHETASES	May 4, 2011

PCT/US2011/036684 13/698,577	INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF LEUCYL-TRNA SYNTHETASES	May 16, 2011
PCT/US2011/038240 13/700,410	INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF GLUTAMINYL-TRNA SYNTHETASES	May 26, 2011
PCT/US2011/038313 13/700,998	INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF LYSYL-TRNA SYNTHETASES	June 1, 2011

WHEREAS, Fango BioPharma Limited, having its principal place of business at 18/F, Edinburgh Tower, The Landmark, 15 Queen's Road Central, Hong Kong, Special Administrative Region of the People's Republic of China, (the "Assignee"), is desirous of acquiring the entire right, title, and interest in: the invention(s); the applications for patent identified in the table above; the right to file applications for patent of the United States or other countries on the invention(s); any application(s) for patent of the United States or other countries claiming priority to these application(s); any provisionals or other right to recover damages, including royalties, for prior infringements of these applications; and any patent(s) of the United States or other countries that may be granted therefor or thereon.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior agreement with the Assignee, or if the Assignor has already done so via a prior agreement with the Assignee then in confirmation of any obligation to do so in said prior agreement, the Assignor has sold, assigned, transferred, and set over, and by these presents does sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

- (a) the invention(s);
- (b) the applications for patent identified in the table above;
- (c) the right to file applications for patent of the United States or other countries on the invention(s), including all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty;
- (d) any application(s) for patent of the United States or other countries claiming the invention(s);
- (e) any application(s) for patent of the United States or other countries claiming priority to the applications for patent identified in the table above or any application(s) for patent claiming the invention(s), including any division(s), continuation(s), and continuation(s)-in-part;


- (f) any provisional or other right to recover damages, including royalties, for prior infringements of any application for patent identified in the preceding paragraphs (b)-(e); and
- (g) any patent(s) of the United States or other countries that may be granted for or on any application for patent identified in the preceding paragraphs (b) - (e), including any reissue(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is the sole and lawful owner of the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein.

The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said applications, and said patents, including interference proceedings, without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

The Assignor hereby requests the Commissioner of Patents to issue said patents of the United States to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

Date: 21 Dec 2012By: 

Wing-Size Lo

I certify that I know or have satisfactory evidence that Wing-Size Lo signed this instrument of his/her own free will, as a voluntary act for the uses and purposes mentioned in the instrument.

Date 21 Dec 2012
(Type or Print)Signed at Hong KongLau Ching Fung
(Type or Print Name of Witness)
(Signature of Witness)